Literature DB >> 10072056

Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma.

J Grill1, D Couanet, C Cappelli, J L Habrand, D Rodriguez, C Sainte-Rose, C Kalifa.   

Abstract

Occlusive vasculopathy is a potential complication of radiotherapy in children with optic pathway glioma. With a median follow-up of 7 years, 13 of 69 children in this study developed clinical and radiological signs of occlusive vasculopathy after radiotherapy within a median interval of 36 months. The major risk factor was neurofibromatosis type 1. Radiotherapy should no longer be the first treatment in these settings. When radiotherapy is unavoidable, regular screening for cerebral vasculopathy is mandatory, as preventive treatment is available.

Entities:  

Mesh:

Year:  1999        PMID: 10072056     DOI: 10.1002/1531-8249(199903)45:3<393::aid-ana17>3.0.co;2-b

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

1.  Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.

Authors:  Andrea Maria Cappellano; Antonio Sergio Petrilli; Nasjla Saba da Silva; Frederico Adolfo Silva; Priscila Mendes Paiva; Sergio Cavalheiro; Eric Bouffet
Journal:  J Neurooncol       Date:  2014-11-01       Impact factor: 4.130

Review 2.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 3.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

4.  Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.

Authors:  Brett J Theeler; Benjamin Ellezam; Shlomit Yust-Katz; John M Slopis; Monica E Loghin; John F de Groot
Journal:  J Neurol       Date:  2014-05-25       Impact factor: 4.849

Review 5.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach.

Authors:  John-Paul Kilday; Ute Bartels; Annie Huang; Mary Barron; Mary Shago; Matthew Mistry; Nataliya Zhukova; Normand Laperriere; Peter Dirks; Cynthia Hawkins; Eric Bouffet; Uri Tabori
Journal:  J Neurooncol       Date:  2013-11-12       Impact factor: 4.130

8.  Remission of a chiasmatic glioma in a non-NF1 patient after brief chemotherapy with vincristine and carboplatin: case report and literature review.

Authors:  Elpis Mantadakis; Maria Raissaki; Vassiliki Danilatou; Alexander Kambourakis; Eftichia Stiakaki; Maria Kalmanti
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 9.  High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance.

Authors:  Melissa M Hudson; Daniel A Mulrooney; Daniel C Bowers; Charles A Sklar; Daniel M Green; Sarah S Donaldson; Kevin C Oeffinger; Joseph P Neglia; Anna T Meadows; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

10.  Headache as a risk factor for neurovascular events in pediatric brain tumor patients.

Authors:  Sarah M Kranick; Cynthia J Campen; Scott E Kasner; Sudha K Kessler; Robert A Zimmerman; Robert A Lustig; Peter C Phillips; Lauren A Beslow; Rebecca Ichord; Michael J Fisher
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.